Literature DB >> 18728020

B-cell involvement in chronic graft-versus-host disease.

Rick Kapur1, Saskia Ebeling, Anton Hagenbeek.   

Abstract

Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected. Chronic graft-versus-host disease is an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. This article reviews the pathogenesis of chronic graft-versus-host disease. In particularly, the role of B cells in chronic graft-versus-host disease is evaluated, as is evident from several studies which have investigated the presence of antibodies as well as studies which have analyzed B cells as a target for immunotherapy. Thirty autoantibodies and 5 alloantibodies have been identified in chronic graft-versus-host disease patients in 24 studies, and 8 autoantibodies and 5 alloantibodies seemed to be strongly associated with chronic graft-versus-host disease. In addition, various studies have observed significant improvements in chronic graft-versus-host disease using the anti-CD20(+) antibody rituximab. However, it appears to be highly likely that both B cells as well as T cells are of major importance in chronic graft-versus-host disease. Further research is required to clarify the pathogenesis of chronic graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728020     DOI: 10.3324/haematol.13311

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  21 in total

1.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

Review 3.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

4.  Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.

Authors:  Zhenyi Jin; Xiuli Wu; Shaohua Chen; Lijian Yang; Qifa Liu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2014-01-11       Impact factor: 3.311

Review 5.  State-of-the-art acute and chronic GVHD treatment.

Authors:  Muhammad Omer Jamil; Shin Mineishi
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

6.  An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

Authors:  Isabel Vogler; Sebastian Newrzela; Sylvia Hartmann; Nadine Schneider; Dorothee von Laer; Ulrike Koehl; Manuel Grez
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

7.  Understanding chronic GVHD from different angles.

Authors:  Bruce Blazar; Eric S White; Daniel Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

8.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

Authors:  Corey Cutler; Haesook T Kim; Bhavjot Bindra; Stefanie Sarantopoulos; Vincent T Ho; Yi-Bin Chen; Jacalyn Rosenblatt; Sean McDonough; Phandee Watanaboonyongcharoen; Philippe Armand; John Koreth; Brett Glotzbecker; Edwin Alyea; Bruce R Blazar; Robert J Soiffer; Jerome Ritz; Joseph H Antin
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

9.  Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Authors:  Edouard Forcade; Haesook T Kim; Corey Cutler; Kathy Wang; Ana C Alho; Sarah Nikiforow; Vincent T Ho; John Koreth; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2016-03-04       Impact factor: 22.113

Review 10.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.